Why you should read it?
Making the wrong choices when selecting auto-injector platform can potentially lead to a recall from the market resulting in a billion-dollar loss. Technolution’s team of specialists have spent years helping clients bridge the gap between device and drug on end-to-end device development projects. With deep industry knowledge, we help clients identify the best device solutions for their needs and reduce risk and time to market. Get our best insights here.
Avoid billion-dollar losses: Choose the right auto-injector platform.
Customized solutions: Identify the perfect device for your needs.
Accelerate to market: Reduce risk and time with our insights.
Industry expertise: Our specialists streamline end-to-end device development.
Choosing the right platform – a critical decision
The challenges in choosing auto-injectors can cause pharma companies to spend excessive time on drug delivery devices as opposed the actual drug development. Additionally, developing an auto-injector from scratch is complex and requires vast engineering know-how, while standard auto-injector platforms offered by OEMs often lack the needed customization options. Assessing the best-fit platform therefor remains a challenge that must avoid neglecting patient needs that could lead to health risk or recall.
Technolution provides the needed capabilities in assessing and developing injection devices, that will ultimately minimize the risks involved for the drug developers. Combining our nerdy expertise with human skills, our team excel in technical and organizational challenges, ensuring alignment between drug and device development from assessment to design transfer.
Over the years, we have helped Pharma & MedTech companies create high-quality products, utilizing our auto-injector platform assessment procedure and toolbox to compare,and evaluate available options based on factors like user needs and drug properties.
In our experience, the best results are achieved by adapting the device to the drug – not the other way around. This founding idea is supported by the three outlined criteria when evaluating specific injection device platforms: use related assessment, technical assessment, and vendor assessment.
However, timing of the platform assessment itself must be equally prioritized. In general, the earlier the involvement, the better. By bringing in specialized engineers, preferably before the end of phase 1, risks of misaligning drug and device are minimized while reducing market delays.
Choosing the right auto-injectors is crucial for pharma companies, but it often leads to excessive time spent on device selection rather than drug development.
Developing auto-injectors from scratch is complex, and standard platforms lack customization options. Finding the best-fit platform is challenging, as patient needs must not be neglected to avoid health risks or recalls.
Technolution specializes in assessing and developing injection devices, reducing risks for drug developers. Our expert team bridges technical and organizational challenges, ensuring alignment between drug and device development, from assessment to design transfer. We’ve helped Pharma & MedTech companies create high-quality products by evaluating options based on user needs and drug properties.
Our approach focuses on adapting the device to the drug, supported by three key criteria: use-related assessment, technical assessment, and vendor assessment. Early platform assessment, ideally before phase 1, is crucial to minimize misalignment risks and market delays, making specialized engineers invaluable.